New Weight Loss Drug Survodutide Shows 16.6% Weight Loss in Trial: How It Compares to Zepbound

A new experimental weight loss drug called survodutide has shown promising results in a late-stage clinical trial, helping people lose an average of 16.6% of their body weight.

The drug, developed by the German biopharmaceutical company Boehringer Ingelheim, works differently from many current weight loss medications. It activates two types of hormone receptors in the body: GLP-1 and glucagon. This dual action may help with both weight loss and liver health.

The Phase 3 trial, called SYNCHRONIZE-1, included 725 adults who were overweight or had obesity but did not have type 2 diabetes. The study took place at multiple locations around the world and lasted 76 weeks, ending in April 2026.

Participants who received weekly injections of survodutide lost an average of 16.6% of their starting body weight. That equals about 39.2 pounds. In comparison, people who received a placebo lost only 3.2% of their body weight.

Up to 85.1% of people taking survodutide lost at least 5% of their body weight, compared to just 38.8% in the placebo group. The weight loss mainly came from fat, not muscle, according to the researchers.

The drug also reduced waist circumference, which is a key measure of belly fat and a sign of metabolic health. Smaller waist sizes are linked to lower risks of heart disease and other health problems.

Is survodutide safe and effective?

Survodutide (also known as BI 456906) is similar to tirzepatide, the active ingredient in Mounjaro and Zepbound, because both drugs combine two mechanisms of action. However, survodutide targets a different pair of hormone receptors.

GLP-1 receptor agonists help with weight loss by reducing appetite and making people feel fuller. Survodutide goes further by also activating glucagon receptors, which are thought to help regulate how the liver processes fat and energy.

This extra action may help reduce fat stored in the liver, which could lower liver inflammation and scarring. These are two main causes of obesity-related liver problems.

In the trial, participants received weekly injections of either 3.6 milligrams or 6.0 milligrams of survodutide, or a placebo. The main goals were to measure body weight changes and the number of people who lost at least 5% of their weight after 76 weeks.

Common side effects included nausea and vomiting, which are typical for GLP-1 drugs. These were mostly mild to moderate and went away over time. They happened most often early in the study when the dose was being increased. No new safety concerns were found.

The full results will be presented at the American Diabetes Association 2026 Scientific Sessions in June 2026.

How does survodutide compare to other weight loss drugs?

Dr. Hector Perez, a lead bariatric surgeon at Renew Bariatrics, told Healthline it is too early to call survodutide a “game-changer.” He noted that other strong weight loss drugs already exist.

“In real life, the best drug is often the one patients can actually stay on,” said Perez, who was not involved in the trial.

But Perez added that survodutide may be especially useful for people with liver disease. Many of his patients have fatty liver, high liver enzymes, insulin resistance, and belly fat, not just obesity.

Survodutide may help the liver by fixing the underlying metabolic problems that cause fatty liver, such as excess body fat, insulin resistance, and inflammation. Its appetite-reducing effect can lower the amount of fat stored in the liver, while its glucagon action may help the body burn more fat, including harmful liver fat.

“If this drug truly improves liver inflammation and fibrosis markers while driving weight loss, that’s where it could carve out a real niche,” Perez said.

What to ask your doctor about weight loss drugs

Kristin Kuminski, a registered dietitian nutritionist with The RX Index who was not involved in the trial, called the results “significant.” She said survodutide appears to work about as well as tirzepatide.

However, she noted that survodutide is not yet approved for use. For now, people should talk to their doctors about what is coming in the future, whether current GLP-1 options are working for them, and whether they might want to join a survodutide trial.

Perez added that people should also ask practical questions before starting any weight loss medication, such as whether they are a good candidate for bariatric surgery. He warned that many people spend years trying medications when surgery could have given them better long-term results.

Other questions to discuss with your doctor include whether weight loss is realistic for your body, how to protect muscle while losing weight, what side effects to expect, what happens if you stop the medication, and whether your insurance will cover the cost.

“Basically, my advice is to choose your treatment according to your body, your habits, your finances, and what you can realistically sustain for years instead of getting impressed with a shiny new drug,” Perez said.

Source: Healthline